The following article is a part of conference coverage from the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, being held in Atlanta, Georgia. The team at MPR will be reporting on the latest news and research conducted by leading experts in rheumatology. Check back for more from the 2019 ACR/ARP Annual Meeting.


Tildrakizumab-asmn demonstrated significant improvements to swollen and tender joint counts and pain in patients with active psoriatic arthritis (PsA), according to phase 2b interim results presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) annual meeting held November 8-13 in Atlanta, Georgia.

The randomized, double-blind, placebo-controlled, phase 2b study evaluated the efficacy and safety of tildrakizumab-asmn in 391 patients with active PsA. Patients were randomized 1:1:1:1 to receive tildrakizumab-asmn 200mg every 4 weeks (Q4W), 200mg every 12 weeks (Q12W), 100mg every 12 weeks, 20mg every 12 weeks to week 24, or placebo. Efficacy of tildrakizumab-asmn was measured on 66 swollen and 68 tender joint counts and pain at week 24 using a visual analog scale (0-100mm).

Results showed statistically significant improvements in pain for the tildrakizumab-asmn 100mg Q12W, 200mg Q12W, and 200mg Q4W treatment arms compared with placebo (P =.0039, P =.0056, and P =.0003, respectively). At week 24, patients treated with tildrakizumab-asmn 100mg Q12W and 200mg Q4W demonstrated statistically significant reductions in swollen joint counts vs placebo (P =.0189 and P =.0111, respectively). Additionally, the tildrakizumab-asmn 100mg and 200mg Q12W treatment arms showed a statistically significant reduction in the number of tender joint counts vs placebo (P =.0140 and P =.0234, respectively).


Continue Reading

Related Articles

With regard to safety, there were no reports of malignancies, major adverse cardiac events, or deaths. The most common adverse events at week 24 were nasopharyngitis, headache and hypertension.

Tildrakizumab-asmn, an interleukin-23 antagonist, is already approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The product is supplied as a 100mg/mL solution for subcutaneous injection in single-dose prefilled syringes.

Visit MPR for live coverage and more news from the 2019 ACR/ARP Annual Meeting.


Reference

Orbai A, Ballerini R, Chou R, et al. Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain. Presented at: 2019 ACR/ARP Annual Meeting; November 8-13; Atlanta, GA. Abstract 1821.